Notably, a multicenter study investigating the biomarkers of immune checkpoint inhibitor response in patients with MMR-D colorectal cancer identified BRAF V600 mutations and specific types of MMR genes as a predictor of worse 12- and 24-month PFS rates [20]. This evidence concerns the gene MRC1 and colorectal cancer.